Mr. Boggs is a managing partner at Revelation Partners. He is also a managing partner at Leerink Revelation Healthcare Funds I & II as well as Revelation Alpine. Prior to joining Leerink Revelation Partners, Mr. Boggs was a vice president at Saints Capital, where he originated and valued investments in the healthcare and consumer-related technology sectors. Prior to joining Saints Capital, Mr. Boggs worked within the Healthcare Group at RBC Capital Markets, where he executed over $1 billion in both private and public transactions.
Some of Mr. Boggs’ past and current investments include: 23andMe, Adaptive Biotechnologies (ADPT), AngioScore (acquired by Spectranetics), CardioMems (acquired by St. Jude), ClearCorrect (acquired by Straumann), Colorescience, Estech (acquired by Atricure), Raindance (acquired by BioRad), Surgiquest (acquired by Conmed), Prolacta Biosciences, Progyny (PGNY), Pulmonx, Trivascular (acquired by Endologix), TEI Biosciences (acquired by Integra Life Sciences), and ViewRay (VRAY).
Mr. Boggs has served on several boards including AngioScore, Clear Correct, Estech, Raindance and Vertos Medical. He has also served on several venture fund Advisory Boards during liquidation including Kearny Venture Partners and the Thomas Weisel Healthcare Venture Fund.
Mr. Boggs actively supports the Cal Berkeley Rugby Endowment, the Challenged Athletes Foundation (CAF), and the La Jolla High School Foundation.
Mr. Boggs received a BS degree in Business from the Haas School of Business at the University of California, Berkeley.